



Chapter I: Introduction: Cancer is a deadly disease with second highest mortality rate. Existing 
treatment strategies kill not only tumor cells but also non-cancerous healthy body cells leading to severe 
adverse side effects of cancer treatment. Among the modern therapeutic modalities, targeted 
chemotherapy and cancer immunotherapy (the therapeutic modality that exploit body’s own immune 
systems) approaches are emerging out to be the most promising for combating the dreaded disease of 
cancer. 
Targeted chemotherapy is the most widely used current treatment modality for cancer which involves 
selective delivery of anti-cancer chemotherapeutics (potent anti-cancer drug or siRNA) to tumor tissue. 
Distinguishing biomarkers over-expressed on tumor cell-surface are utilized for selective delivery of 
anticancer chemotherapeutics to tumor tissue with minimal harm to other healthy tissue.  
Cancer Immunotherapy exploits body’s own immune cells (e.g., dendritic cells, natural killer cells, T-
cells, etc.) to fight against cancer. There are many types of cancer immunotherapy including monoclonal 
antibodies, oncolytic virus therapy, cancer vaccines, etc. Dendritic cell (DC) based genetic immunization 
(DNA vaccination) has shown lot of promises because of their unique potential to simultaneously induce 
both humoral and cellular immune responses against tumors. In DC-based DNA vaccination, dendritic 
cells (body’s most promising antigen presenting cells) are transfected with plasmid DNA encoding 
distinguishing tumor associated antigen. DCs process the expressed tumor antigen and present the 
processed antigenic fragments on their cell surfaces with the help of major histocompatibility complexes 
MHC-I and MHC-II. MHC bound antigenic fragments on DC-surface are recognized by T cells and the 
activated T-cells thereafter get triggered to start rapid proliferation. The activated T-cells recognize the 
tumor cells expressing the particular antigen and induce intense humoral & cellular immune responses 
against the tumor cells. However, either only targeted chemotherapy or only DC-based Immunotherapy 
hardly results in long-lasting overall survivability of tumor bearing mice. 
Liposomes, the spherical molecular assembly of amphiphiles (often having size within the range 100-200 
nm) with an aqueous interior enclosed by lipid bi-layer, have long been used for targeted delivery of 
bioactives selectively to destined tissue under in vivo settings. In targeted chemotherapy, targeting of 
liposomally entrapped chemotherapeutics to tumor cells are achieved using liposomes made from 
amphiphilic molecule covalently connected with a tumor targeting ligands in their exo-surface regions. 
The liposomes covalently grafted with such a tumor-targeting ligand can target specific receptors over 
expressed in cancerous cells. Such tumor targeting liposomes can encapsulate both hydrophilic 
drug/siRNA (encapsulate inside aqueous compartment) & hydrophobic drug (encapsulate in hydrophobic 
lipid bi-layer) and deliver their therapeutic payloads/cargo (cytotoxic genes/siRNAs, small molecule anti-
cancer drugs, etc.) to the cancerous tissues without affecting normal tissue (Figure 1). However efficient 
and selective targeting of potent cancer therapeutics to tumor cells/tissues remains a difficult challenge. 




Figure 1: Cartoon for Tumor Targeting Liposomes. 
In the present thesis, I report on the development and bio-activity evaluation of two new liposomal 
drug delivery systems for delivering potent cancer therapeutics to neuroblastoma and glioblastoma in 




Chapter II: Development of CDC20siRNA and Paclitaxel co-loaded new liposomal nanocarrier 
for combating neuroblastoma 
Despite significant recent progresses in neuroblastoma treatment, accomplishing markedly enhanced 
overall survivability remains an arduous task mostly due to tumor relapse and/or drug-resistant 
tumors. CDC20, a key cell cycle regulator protein required to complete mitosis, is over expressed in 
many cancer cells and therapeutic strategies based on selective delivery of CDC20siRNA to tumor & 
tumor vasculatures hold promise for combating cancer. Prior reports demonstrate that human 
neuroblastoma cells IMR-32 express functional GABAa receptor on their surface and nipecotic acid 
is a GABA related compound widely used as an inhibitor of both glial and neuronal GABA uptake. 
Chapter II of my doctoral thesis reports on the development of a novel GABAa receptor targeting 
circulation stable liposomal system prepared from nipecotic acid-derived cationic amphiphile 
(NACA) for combating neuroblastoma (Figure 2). I have demonstrated that liposomes of NACA can 
efficiently encapsulate siRNAs inside its inner hydrophilic core and protects them from attack by 
RNase. Findings in the cellular uptake study demonstrated that liposome of NACA delivers siRNA to 
human neuroblastoma IMR-32 cells via GABAa receptor. CDC20siRNA-loaded liposome of NACA 
silenced CDC20 gene  expression in IMR-32 cell.  Prior studies reported that silencing of CDC20 
gene sensitizes cancer cells to paclitaxel (PTX). I have exploited this prior findings in my doctoral 
thesis work.  Importantly, I have demonstrated that administration of NACA-liposomes containing 
co-encapsulated CDC20siRNA & PTX induces significant tumor growth inhibition in athymic nude 
mice bearing xenografted human neuroblastoma (Figure 2, taken from S. Bhunia, R.Vegesna and A. 
Chaudhuri, manuscript accepeted in Nanoscale, 2016, DOI: 10.1039/C6NR07532K, Accepted 









Figure 2: Intravenous administration of CDC20 siRNA and paclitaxel (PTX) co-encapsulated within 
liposomes of NACA significantly inhibits growth of human neuroblastoma xenografted in athymic nude mice. 
 
Chapter III: Combating orthotopically established mouse glioblastoma using targeted 
Chemotherapy in combination with in vivo dendritic cell targeted cancer immunotherapy  
 
Despite remarkable advances in glioblastoma treatments during the past decade, accomplishing 
significantly enhanced overall survivability (OS) remains a formidable challenge. STAT3, a key 
signal transduction protein, is activated in numerous cancer cells including glioblastoma. Inhibition 
of STAT3 leads to apoptosis in tumor cells and enhanced DC-maturation (through up regulated 
expressions of MHC class II, co-stimulatory molecules CD80, CD86, etc.). Major obstacle for 
systemic chemotherapy of glioblastoma is the presence of Blood Brain barrier (BBB) which limits 




chemotherapeutics selectively to brain tumors are exploiting some receptor and transporter molecule 
over expressed on the brain capillary endothelial cells (BCECs) of BBB. Large Amino Acid 
Transporter type -1 (LAT-1) is abundantly and selectively expressed not only on BCECs of BBB but 
also in many types of cancers including glioblastoma multiforme. Chapter III of the present thesis 
delineates development of a novel BBB-crossing liposomal drug carrier for targeting potent 
chemotherapeutics selectively to orthotopically established mouse glioblastoma.  The liposomes were 
prepared using a novel amphiphilic molecule (Amphi-DOPA) containing the well known BBB-
crossing L-3,4-dihydroxyphenyl alanine (L-DOPA, a potent drug for treatment of Parkinson’s 
disease that crosses BBB via LAT-1) moiety covalently grafted in its polar head-group region and 
two n-hexadecyl hydrophobic tails in its non-polar region. I have demonstrated that liposomes of 
Amphi-DOPA containing encapsulated WP1066 (a commercially available small molecule STAT3 
inhibitor) significantly inhibit growth of orthotopic glioblastoma in BL6J/C57 mice by down 
regulating p-STAT3 under in vivo conditions. Furthermore, I have shown that targeted chemotherapy 
using WP1066-loaded liposomes of Amphi-DOPA, when used in combination with in vivo dendritic 
cell targeted genetic immunization (with a recently reported in vivo DC-targeting liposomes from our 
group in complexation with survivin encoded DNA vaccine), elicits significantly enhanced overall 










Figure 3: Targeted chemotherapy in combination with in vivo dendritic cell targeted DNA 
vaccination leads to significant enhancement of survivability in orthotopic glioblastoma 
bearing mice.  
Conclusion: The present thesis describes design, synthesis and bio-activity evaluation of two novel 
amphiphilic molecules. The liposomes of the first amphiphile, upon intravenous administration, 
showed efficient targeting of their drug payloads selectively to neuroblastoma and causes significant 
tumor growth inhibition. Intravenously administered liposomes of the second amphiphile resulted 
into significant inhibition of orthotopically established mouse glioblastoma. The findings described 
in Chapter III of the present thesis demonstrate that targeted chemotherapy in combination with in 
vivo dendritic cell targeted DNA vaccination leads to significant survivability enhancement in 
orthotopic glioblastoma bearing mice.  
